FindTrial
Sign In

Homoeopathic treatment of vaginal symptoms in menopausal women

Effectiveness of individualized homoeopathic medicines versus Fagopyrum esculentum in treatment of vulvovaginal symptoms in post-menopausal women: An open-label randomized pragmatic clinical trial

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/03/012572
Enrollment
60
Registered
2018-03-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Post-menopausal vulvo-vaginitis Health Condition 2: N952- Postmenopausal atrophic vaginitis

Interventions

Intervention1: Fagopyrum esculentum in centesimal or 50 millesimal potencies: In centesimal scale, each dose consist of a single drop of Fagopyrum esculentum (preserved in 90% v/v ethanol) in 5 ml of
dosage and repetition depending upon the individual requirement of the cases. In 50 millesimal scale, a single medicated cane sugar globule of poppy seed size (no. 10) will be dissolved in 90 ml disti
16 doses to be marked on the vial
each dose of 5 ml to be taken after 10 uniformly forceful downward strokes to the vial in 45 ml normal water in a clean cup, to stir well, to take 5 ml of this liquid orally, and to discard rest of th
dosage and repetition depending upon the individual requirement of the cases. In 50 millesimal scale, a single medicated cane sugar globule of poppy seed size (no. 10) will be dissolved in 90 ml disti
16 doses to be marked on the vial
each dose of 5 ml to be taken after 10 uniformly forceful downward strokes to the vial in 45 ml normal water in a clean cup, to stir well, to take 5 ml of this liquid orally, and to discard rest of th

Sponsors

National Institute of Homoeopathy Ministry of AYUSH Govt of India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Postmenopausal women suffering from vulvo-vaginal symptoms for at least last 3 months 2. Age: 45-60 years 3. Ability to read Bengali 4. Patients giving written consent to participate 5. Any standard or CAM therapy, if ongoing, discontinued for at least 1 month

Exclusion criteria

Exclusion criteria: 1. Patients with known vulvar dermatoses including: Lichen Sclerosus, Lichen Planus, Psoriasis, Behcetâ??sdisease, Hidradenitis Suppurativa, Anorectal Crohnâ??s disease, or Genital Herpes 2. Patients who had an artificial menopause and were on HRT 3. Patients having history of breast or reproductive organ cancer 4. Major gynecological surgery in last 6 months 5. Patients with psychiatric diseases. 6. Cases suffering from uncontrolled systemic illness or life-threatening infections 7. Cases already undergoing homoeopathic treatment for any chronic disease 8. Substance abuse and/or dependence 9. Self-reported immune-compromised state

Design outcomes

Primary

MeasureTime frame
Vulvo-vaginal symptom questionnaire (VSQ); translated Bengali versionTimepoint: Baseline and after 3 months—

Secondary

MeasureTime frame
Utian Quality of Life (UQOL) questionnaire; translated Bengali versionTimepoint: Baseline and after 3 months—

Countries

India

Contacts

Public ContactAbhijit Chattopadhyay

National Institute of Homoeopathy, Ministry of AYUSH, Govt. of India

drac.nih@gmail.com7003547446

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026